Allied-SCT to List on OTC Market in Late June, Targeting Natural Colorant Market Opportunity
Allied-SCT, a major manufacturer of carotenoid products, plans to list on the OTC market in late June with a tentative underwriting price of NT$20 per share. COO Yang Bin stated that with California set to ban certain artificial colors in public school cafeterias starting at the end of 2027, Allied-SCT's natural carotenoid products are poised to capture a US$300 million market opportunity.
📋 Article Processing Timeline
- 📰 Published: May 21, 2026 at 21:10
- 🔍 Collected: May 21, 2026 at 21:31 (21 min after Published)
- 🤖 AI Analyzed: May 21, 2026 at 21:41 (9 min after Collected)
Taipei, May 21 (CNA) – Allied-SCT, a major manufacturer of carotenoid products and professional biotech raw materials, will be listed on the OTC market in late June with a tentative underwriting price of NT$20 per share. COO Yang Bin stated that as California will ban public school cafeterias from serving foods containing related artificial colors starting at the end of next year, Allied-SCT's carotenoid products are poised to capture a US$300 million market opportunity. Allied-SCT held a media briefing today, where Chairman Yang Cheng-li said the company has been deeply involved in carotenoids for over 20 years and is currently one of the main suppliers in the global synthetic carotenoid market. It is also one of the few suppliers in Asia with the capability to mass-produce a series of products including β-carotene, canthaxanthin, lycopene, and lutein. Allied-SCT's revenue for April this year was NT$103 million, a year-on-year increase of 14.73%; its cumulative revenue for the first four months of this year reached NT$343 million, a year-on-year increase of 14.62%. He pointed out that the manufacturing technology for carotenoids has a very high barrier to entry, not only because of the complex process but also due to long customer certification times, strict quality requirements, and the need for products to comply with various national regulations. Additionally, market information is relatively closed, creating a significant entry barrier. Since Roche (now DSM) in Switzerland successfully synthesized β-carotene in 1954, the market has been dominated by three main players for over 70 years: Allied-SCT, DSM of the Netherlands, and BASF of Germany. Yang Cheng-li stated that the company's core competitiveness lies in its dual engine of "synthesis technology plus formulation technology." Currently, its own brand is sold in over 60 countries and has penetrated the supply chains of the world's top 3 food, beverage, and dairy clients, as well as the top 5 flavor and fragrance companies. Yang Bin said that with stricter global food regulations, the trend of replacing artificial colors with natural ones is becoming clearer. The U.S. FDA has announced a goal to phase out six artificial colors, including Red 40, Yellow 5, and Yellow 6, from food by the end of 2026. California also passed a Food Safety Act in 2024, which is expected to prohibit public school cafeterias from serving foods with related artificial colors starting at the end of 2027. Yang Bin pointed out that Allied-SCT's carotenoid products, covering a full spectrum from yellow to red, are expected to become an important solution for food companies to replace artificial colors. As sample testing with several major U.S. food manufacturers continues to progress, once certification is completed and mass production begins, it is expected to inject a new wave of growth momentum for Allied-SCT. (Editor: Pan Yi-ching) 1150521
FAQ
立弘公司主要業務是什麼?
根據新聞內容,立弘是一家專業生技原料大廠,主要生產類胡蘿蔔素產品,如β-胡蘿蔔素、胡蘿蔔醛、甘蔗紅素、番茄紅素與葉黃素等。
立弘預計何時掛牌上櫃?承銷價是多少?
立弘預計於6月下旬掛牌上櫃,暫定每股承銷價為新台幣20元。
立弘看好什麼市場商機?
立弘看好全球食品法規趨嚴,天然色素替代人工色素的商機。特別是美國加州預計於2027年底起禁止公立學校餐廳使用相關人工色素,公司認為其類胡蘿蔔素產品有望搶攻約3億美元的市場。
立弘近期的營收表現如何?
立弘今年4月營收為新台幣1.03億元,年增14.73%;今年前4月累計營收達3.43億元,年增14.62%。
類胡蘿蔔素市場的主要競爭者有誰?
根據報導,市場長期主要由立弘、荷蘭DSM與德國BASF等三家業者主導。